{"schema_version":"secwatch.filing_event.v1","accession":"0001464521-26-000040","form_type":"8-K","ticker":"HTFL","cik":"0001464521","company_name":"Heartflow, Inc.","filed_at":"2026-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.124644+00:00","generated_at":"2026-05-15T09:50:53.704107+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Heartflow Q4 revenue $49.1M (+40% YoY); FY2025 revenue $176M; guides FY2026 revenue $218-222M","bullets":["Q4 revenue $49.1M (+40% YoY); gross margin 79.5%; net loss $24.4M ($0.29/share).","Full year 2025 revenue $176M (+40% YoY); net loss $116.8M ($3.17/share).","FY2026 guidance: revenue $218M-$222M (24%-26% growth); non-GAAP gross margin 80-81%.","U.S. installed base 1,465 accounts; Plaque installed base 489; Aetna coverage brings Plaque covered lives to ~75%.","Warrants fully net exercised; no future noncash warrant revaluation charges; cash $280.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001464521-26-000040","json":"https://secwatch.observer/filing/0001464521-26-000040.json","markdown":"https://secwatch.observer/filing/0001464521-26-000040.md","text":"https://secwatch.observer/filing/0001464521-26-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1464521/000146452126000040/0001464521-26-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1464521/000146452126000040/htfl-20260318x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:50:53.704107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c94bc1ca8d9097373270e4e0b767b9b06890ec2c","claim":"Heartflow, Inc. reported the quarter and full year ended December 31, 2025 results: revenue $49.1 million, net income $(0.29) net loss per share.","evidence_excerpt":"artery disease (CAD), today reported financial results for the fourth quarter and full year ended Dec ember 3 1 , 2025.  Fourth Quarter 2025 Highlights \" Total revenue of $49.1 million, a 40% increase year-over-year \" Gross margin of 79.5%, non-GAAP gross margin of 79.9% \" Net operating loss of $17. 8 million, non-GAAP net operating loss of $12.5 million \" U.S.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1464521/000146452126000040/0001464521-26-000040-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and full year ended December 31, 2025"},{"label":"Revenue","value":"$49.1 million"},{"label":"Net income","value":"$(0.29) net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}